Juvenile dermatomyositis: New insights and new treatment strategies

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 1, 2012, Pages 41-50

  Martin, Neil ^a   Li, Charles K ^a   Wedderburn, Lucy R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

dermatomyositis; idiopathic inflammatory muscle disease; juvenile; myopathy

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; HLA ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ALGORITHM; ALLELE; CALCINOSIS; CELLULAR IMMUNITY; DERMATOMYOSITIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOPLASMIC RETICULUM STRESS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; JUVENILE DERMATOMYOSITIS; MEDICAL ASSESSMENT; MUSCLE EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY JUVENILE DERMATOMYOSITIS; REFRACTORY MYOSITIS; REVIEW; SKIN EXAMINATION; UNSPECIFIED SIDE EFFECT;

EID: 84863118543     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11424460     Document Type: Article

References (81)

1. Al-Mayouf S.M. Laxer R.M. Schneider R. Silverman E.D. Feldman B.M. (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27 (10): 2498–2503.
2. Bitnum S. Daeschner C.W. Jr Travis L.B. Dodge W.F. Hopps H.C. (1964) Dermatomyositis. J Pediatr 64: 101–131.
3. Bode R.K. Klein-Gitelman M.S. Miller M.L. Lechman T.S. Pachman L.M. (2003) Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 49 (1): 7–15.
4. Bohan A. Peter J.B. (1975 a) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (7): 344–347.
5. Bohan A. Peter J.B. (1975 b) Polymyositis and dermatomyositis (second of two parts). N Engl JMed 292 (8): 403–407.
6. Brown V.E. Pilkington C.A. Feldman B.M. Davidson J.E. (2006) An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 45 (8): 990–993.
7. Casciola-Rosen L. Nagaraju K. Plotz P. Wang K. Levine S. Gabrielson E. et al. (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201 (4): 591–601.
8. Chinoy H. Lamb J.A. Ollier W.E.R. Cooper R.G. (2009 a) An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. Curr Opin Rheumatol 21 (6): 588–593.
9. Chinoy H. Payne D. Poulton K.V. Fertig N. Betteridge Z. Gunawardena H. et al. (2009 b) HLA-DPB1 associations differ between DRB1*03 positive anti and anti antibody positive idiopathic inflammatory myopathy. Rheumatology 48 (10): 1213–1217.
10. Chinoy H. Platt H. Lamb J.A. Betteridge Z. Gunawardena H. Fertig N. et al. (2008) The protein tyrosine phosphatase N 22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 58 (10): 3247–3254.
11. Chinoy H. Salway F. Fertig N. Shephard N. Tait B.D. Thomson W. et al. (2006) In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 8 (1): R13.
12. Chinoy H. Salway F. John S. Fertig N. Tait B.D. Oddis C.V. et al. (2007) Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 46 (9): 1411–1416.
13. Christen-Zaech S. Seshadri R. Sundberg J. Paller A.S. Pachman L.M. (2008) Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 58 (2): 571–576.
14. Cooper M.A. Willingham D.L. Brown D.E. French A.R. Shih F.F. White A.J. (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56 (9): 3107–3111.
15. Dagher R. Desjonquères M. Duquesne A. Quartier P. Bader-Meunier B. Fischbach M. et al. (2010) Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 9 December [Epub ahead of print].
16. Dalakas M.C. Illa I. Dambrosia J.M. Shawke A.S. Stein P.D. Otero C. et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 (27): 1993–2000.
17. Eloranta M-L. Barbasso Helmers S. Ulfgren A.K. Ronnblom L. Alm G.V. Lundberg I.E. (2007) A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 56 (9): 3112–3124.
18. Elst E.F. Klein M. de Jager W. Kamphuis S. Wedderburn L.R. van der Zee R. et al. (2008) Hsp 60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 58 (2): 547–555.
19. Emslie-Smith A.M. Engel A.G. (1990) Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27 (4): 343–356.
20. Fall N. Bove K.E. Stringer K. Lovell D.J. Brunner H.I. Weiss J. et al. (2005) Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum 52 (10): 3175–3180.
21. Feldman Brian M. Rider L.G. Reed A.M. Pachman L.M. (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371 (9631): 2201–2212.
22. Fisler R.E. Liang M.G. Fuhlbrigge R.C. Yalcindag A. Sundel R.P. (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47 (4): 505–511.
23. Gunawardena H. Wedderburn L.R. Chinoy H. Betteridge Z.E. North J. Ollier W.E. et al. (2009) Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60 (6): 1807–1814.
24. Gunawardena H. Wedderburn L.R. North J. Betteridge Z. Dunphy J. Chinoy H. et al. (2008) Clinical associations of autoantibodies to a p155/140 k Da doublet protein in juvenile dermatomyositis. Rheumatology 47 (3): 324–328.
25. Hassan J. van der Net J.J. van Royen-Kerkhof A. (2008) Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 27 (11): 1469–1471.
26. Holzer U. van Royen-Kerkhof A. van der Torre P. Kuemmerle-Deschner J. Well C. Handgretinger R. et al. (2010) Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 39 (1): 88–92.
27. Howard O.M.Z. Dong H.F. Yang D. Raben N. Nagaraju K. Rosen A. et al. (2002) Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196 (6): 781–791.
28. Huber A.M. (2010) Update on the assessment of children with juvenile idiopathic inflammatory myopathy. Curr Rheumatol Rep 12 (3): 204–212.
29. Huber A.M. Dugan E.M. Lachenbruch P.A. Feldman B.M. Perez M.D. Zemel L.S. et al. (2008 a) Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis Rheum 59 (2): 214–221.
30. Huber A.M. Feldman B.M. (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7 (6): 441–446.
31. Huber A.M. Feldman B.M. Rennebohm R.M. Hicks J.E. Lindsley C.B. Perez M.D. et al. (2004) Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50 (5): 1595–1603.
32. Huber A.M. Giannini E.H. Bowyer S.L. Kim S. Lang B. Lindsley C.B. et al. (2010) Protocols for the initial treatment of moderately severe Juvenile dermatomyositis: results of a children's Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 62: 219–225.
33. Huber A.M. Lachenbruch P.A. Dugan E.M. Miller F.W. Rider L.G. (2008) Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 59 (3): 352–356.
34. Huber A.M. Lang B. LeBlanc C.M. Birdi N. Bolaria R.K. Malleson P. et al. (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 (3): 541–549.
35. Isenberg D.A. Allen E. Farewell V. Ehrenstein M.R. Hanna M.G. Lundberg I.E. et al. (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 43 (1): 49–54.
36. Isenberg D.A. Rowe D. Beverley P.C. (1985) HLA antigen expression in myositis. Lancet 1 (8430): 703.
37. Kim S. Moussa D. Fatma D. Zurakowski D. Fuhlbrigge R.C. Sundel R.P. (2009) Complete and sustained drug free remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 60 (6): 1825–1830.
38. Klein-Gitelman M.S. Waters T. Pachman L.M. (2000) The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 13 (6): 360–368.
39. Li C.K. Knopp P. Moncrieffe H. Singh B. Shah S. Nagaraju K. et al. (2009) Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 175 (3): 1030–1040.
40. Li C.K. Varsani H. Holton J.L. Gao B. Woo P. Wedderburn L.R. et al. (2004) MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 31 (3): 605–609.
41. López de Padilla C.M. Vallejo A.N. Lacomis D. McNallan K. Reed A.M. (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60 (4): 1160–1172.
42. López de Padilla C.M. Vallejo A.N. McNallan K.T. et al. (2007) Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 56 (5): 1658–1668.
43. Lovell D.J. Lindsley C.B. Rennebohm R.M. Ballinger S.H. Bowyer S.L. Giannini E.H. et al. (1999) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 42 (10): 2213–2219.
44. Lundberg I. Ulfgren A.K. Nyberg P. Andersson U. Klareskog L. (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40 (5): 865–874.
45. Lutz J. Huwiler K.G. Fedczyna T. Lechman T.S. Crawford S. Kinsella T.R. et al. (2002) Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol 103(3 Pt 1): 260–263.
46. Maillard S.M. Jones R. Owens C. Pilkington C. Woo P. Wedderburn L.R. et al. (2004) Quantitative assessment of MRI T 2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 43 (5): 603–608.
47. Maillard S.M. Jones R. Owens C. Pilkington C. Woo P. Wedderburn L.R. et al. (2005) Quantitative assessment of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 53 (4): 558–564.
48. Mamyrova G. O'Hanlon T.P. Monroe J.B. Carrick D.M. Malley J.D. Adams S. et al. (2006) Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 54 (12): 3979–3987.
49. Mamyrova G. O'Hanlon T.P. Sillers L. Malley K. James-Newton L. Parks C.G. et al. (2008) Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58 (12): 3941–3950.
50. Martin N. Krol P. Smith S. Murray K. Pilkington C.A. Davidson J.E. et al. (2011 a) A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology 50 (1): 137–145.
51. Martin N. Wedderburn L.R. Pilkington C.A. Davidson J.E. (2011 b) A survey of current practice in the management of Juvenile Dermatomyositis in the UK and Ireland. Abstract from the 17th Paediatric Rheumatology European Society Congress. Clin Exp Rheumatol 29(Suppl.): 372.
52. McCann L.J. Garay S.M. Ryan M.M. Harris R. Riley P. Pilkington C.A. (2007) Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 46 (8): 1363–1366.
53. Miller F.W. Rider L.G. Chung Y.L. Cooper R. Danko K. Farewell V. et al. (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40 (11): 1262–1273.
54. Morita R. Schmitt N. Bentebibel S-E. Ranganathan R. Bourdery L. Zurawski G. et al. (2011) Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34 (1): 108–121.
55. Morris P. Dare J. (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32 (3): 189–191.
56. Nagaraju K. Casciola-Rosen L. Lundberg I. Ranganathan R. Bourdery L. Zurawski G. et al. (2005) Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52 (6): 1824–1835.
57. Nagaraju K. Raben N. Loeffler L. Parker T. Rochon P.J. Lee E. et al. (2000) Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 97 (16): 9209–9214.
58. Niewold T.B. Kariuki S.N. Morgan G.A. Shrestha S. Pachman L.M. (2010) Gene–gene–sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr 157 (4): 653–657.
59. O'Connor K.A. Abbott K.A. Sabin B. Kuroda M. Pachman L.M. (2006) MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 120 (3): 319–325.
60. Pachman L.M. Fedczyna T.O. Lechman T.S. Lutz J. (2001) Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep 3 (5): 379–386.
61. Posalski J.D. Ishimori M.I. Wallace D.J. Weisman M.H. (2009) Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 18 (6): 516–521.
62. Ramanan A.V. Campbell-Webster N. Ota S. Parker S. Tran D. Tyrell P.N. et al. (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52 (11): 3570–3578.
63. Reed A.M. Pachman L. Ober C. (1991) Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol 32 (4): 235–240.
64. Rider L. Lachenbruch P.A. Monroe J.B. Ravelli A. Cabalar I. Feldman B.M. et al. (2011) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the Myositis Damage Index. Arthritis Rheum 60 (11): 3425–3435.
65. Riley P. Maillard S.M. Wedderburn L.R. Woo P. Murray K.J. Pilkington C.A. (2004) Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 43 (4): 491–496.
66. Riley P. McCann L.J. Maillard S.M. Woo P. Murray K.J. Pilkington C.A. (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47 (6): 877–880.
67. Rouster-Stevens K.A. Gursahaney A. Ngai K-L. Daru J.A. Pachman L.M. (2008) Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59 (2): 222–226.
68. Ruperto N. Ravelli A. Murray K.J. Lovell D.J. Andersson-Gare B. Feldman B.M. et al. (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 42 (12): 1452–1459.
69. Ruperto N. Ravelli A. Pistorio A. Ferriani V. Calvo I. Ganser G. et al. (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (1): 4–13.
70. Sallum A.M.E. Marie S.K.N. Wakamatsu A. Sachetti S. Vianna M.A. Silva C.A. et al. (2004) Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 31 (4): 801–807.
71. Schwartz T. Sanner H. Husebye T. Flatø B. Sjaastad I. (2011) Extended report: cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70 (5): 766–771.
72. Seshadri R. Feldman B.M. Ilowite N. Cawkwell G. Pachman L.M. (2008) The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 59 (7): 989–995.
73. Shrestha S. Wershil B. Sarwark J.F. Niewold T.B. Philipp T. Pachman L.M. (2010) Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 62 (9): 2813–2822.
74. Smith R.L. Sundberg J. Shamiyah E. Dyer A. Pachman L.M. (2004) Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 31 (8): 1644–1649.
75. Stringer E. Bohnsack J. Bowyer S.L. Griffin T.A. Huber A.M. Lang B. et al. (2010) Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 37 (9): 1953–1961.
76. Symmons D.P. Sills J.A. Davis S.M. (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34 (8): 732–736.
77. Wedderburn L.R. McHugh N.J. Chinoy H. Cooper R.G. Salway F. Ollier W.E. et al. (2007) HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 46 (12): 1786–1791.
78. Wedderburn L.R. Rider L.G. (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 23 (5): 665–678.
79. Wedderburn L.R. Varsani H. Charman S.C. Amato A.A. (2010) Validation of a histopathological score tool for the measurement of severity in muscle biopsies from patients with juvenile dermatomyositis. Rheumatology 49(Suppl. 1): i116.
80. Wedderburnm L.R. Varsani H. Charman S.C. Marie S.K.N. Amato A.A. (2011) Validation and clinical testing of a standardised assessment of juvenile dermatomyositis muscle biopsy. Neuropathol Appl Neurobiol 37(Suppl. 1): 13.
81. Wedderburn L.R. Varsani H. Li C.K.C. Newton K.R. Amato A.A. Banwell B. et al. (2007) International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: A tool for potential use in clinical trials. Arthritis Rheum 57 (7): 1192–1201.